ALEMBICLTD · NSE
Alembic Limited
₹102.63
-0.09% (-₹0.09)
Prev. close
₹102.72
Volume
8,29,029
Delivery %
58.9%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Alembic Limited
Alembic Limited engages in real estate business in India and internationally. It operates through Active Pharmaceutical Ingredient (API) and Real Estate segments. The company constructs residential and commercial real estate projects; provides project management and marketing consultancy services; and leases commercial properties. It also manufactures and markets fermentation and chemistry based active pharmaceutical ingredients; and research and development activities. In addition, the company is involved in power generation through co-generation plants and wind power sources. It serves individuals, entrepreneurs, corporates, business houses, HNIs, NRIs, and pharmaceutical companies. The company was incorporated in 1907 and is based in Vadodara, India. Alembic Limited is a subsidiary of Nirayu Pvt. Ltd.
Details
Sector
Real Estate
Industry
Real Estate - Development
CEO
Mr. Udit C. Amin
Headquarters
Vadodara
Employees
261
Website
alembiclimited.comExchange
View on NSE ↗Key stats
Market cap
₹2,635.35 Cr
P/E ratio (TTM)
8.2
Dividend yield
2.34%
EPS (TTM)
₹12.49
Beta (1Y · daily vs NIFTY 50)
1.45
Beta (5Y · monthly vs NIFTY 50)
1.75
Shares float
7.14 Cr
EPS · quarter ended Jun 2026
₹2.53
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 7.5% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹73.52 Cr | ₹78.22 Cr | ₹127.24 Cr | ₹157.49 Cr | ₹221.89 Cr | ₹239.99 Cr | |
| EBITDA | ₹21.34 Cr | ₹103.11 Cr | ₹93.99 Cr | ₹111.63 Cr | ₹168.60 Cr | ₹163.43 Cr |
| ₹342.84 Cr | ₹222.06 Cr | ₹190.65 Cr | ₹268.62 Cr | ₹310.68 Cr | ₹317.38 Cr | |
| Diluted EPS | ₹13.35 | ₹8.65 | ₹7.43 | ₹10.46 | ₹12.1 | ₹12.36 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,408.96 Cr | ₹2,631.95 Cr | ₹2,205.00 Cr | ₹2,329.00 Cr | ₹2,503.00 Cr | ₹2,590.00 Cr | |
| — | — | ₹0 | ₹9.15 Cr | ₹14.45 Cr | ₹10.64 Cr | |
| Stockholders' equity | ₹2,297.03 Cr | ₹2,496.58 Cr | ₹2,078.00 Cr | ₹2,185.00 Cr | ₹2,338.00 Cr | ₹2,445.00 Cr |
Current assets, Non-current assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹-2.18 Cr | ₹-17.75 Cr | ₹38.85 Cr | ₹22.69 Cr | ₹86.37 Cr | ₹120.07 Cr | |
| Investing cash flow | ₹-34.74 Cr | ₹18.85 Cr | ₹7.30 Cr | ₹25.84 Cr | ₹-26.58 Cr | ₹-53.86 Cr |
| ₹-15.36 Cr | ₹-5.82 Cr | ₹-46.39 Cr | ₹-48.19 Cr | ₹-58.34 Cr | ₹-67.50 Cr | |
| Capital expenditure | ₹-47.46 Cr | ₹-35.81 Cr | ₹-26.00 Cr | ₹-56.00 Cr | ₹-51.00 Cr | ₹-77.00 Cr |
| End cash position | ₹5.89 Cr | ₹1.17 Cr | ₹93.18 L | ₹1.26 Cr | ₹2.71 Cr | ₹1.41 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 70.88% |
| Public | 29.12% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Real Estate
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| DLF Limited | ₹1.58 L Cr | ₹644.35 | 34.7 | 3.48 | 9.7% | 0.01 | -1.4% | -17.7% |
| Lodha Developers Limited | ₹1.10 L Cr | ₹1,144.7 | 26.8 | 4.73 | 14.7% | 0.42 | +19.2% | -5.0% |
| The Phoenix Mills Limited | ₹66,964.45 Cr | ₹1,877.9 | 52.3 | 6.09 | 11.1% | 0.48 | +16.0% | +15.5% |
| Oberoi Realty Limited | ₹63,292.24 Cr | ₹1,785 | 24.1 | 3.53 | 14.0% | 0.16 | +13.7% | +7.6% |
| Prestige Estates Projects Limited | ₹62,029.46 Cr | ₹1,435.1 | 54.4 | 3.81 | 7.3% | 1.09 | +74.1% | -11.9% |
| Godrej Properties Limited | ₹52,654.39 Cr | ₹1,748 | 32.9 | 2.75 | 9.7% | 0.83 | +4.7% | -14.2% |
| Anant Raj Limited | ₹21,481.05 Cr | ₹606.15 | 36.7 | 3.71 | 9.6% | 0.12 | +21.9% | +3.5% |
| Brigade Enterprises Limited | ₹20,445.49 Cr | ₹620.9 | 31.7 | 3.00 | 9.4% | 1.01 | +12.4% | -34.6% |
| Horizon Industrial Parks Limited | ₹15,040.10 Cr | ₹54.23 | — | 2.74 | -3.4% | 1.26 | +19.7% | — |
| Aditya Birla Real Estate Limited | ₹13,638.67 Cr | ₹1,257.4 | — | 3.69 | -2.8% | 1.52 | -66.4% | -34.9% |
| Sobha Limited | ₹12,721.09 Cr | ₹1,215.2 | 55.0 | 2.70 | 4.1% | 0.22 | +28.3% | -25.4% |
| Alembic Limited | ₹2,540.86 Cr | ₹98.95 | 8.2 | 1.04 | 13.0% | 0.00 | +8.9% | -8.3% |
Ranked by market cap within Real Estate, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
5 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Alembic Pharma shares rise 4% on receiving USFDA EIR for Vadodara facility
Alembic Pharmaceuticals shares rose 4% after receiving an Establishment Inspection Report (EIR) from the USFDA for its Vadodara Bioequivalence Facility. The report signifies the closure of the inspection conducted in March 2025. This positive development contributed to the stock's intraday high.
Pharma sector stocks today, September 17: Panacea Biotech gains 2.27%, Alembic Pharma up 2.13%, Wockhardt rises 2%
Alembic Pharma's stock rose 2.13% to ₹842 during early trading on September 17, 2026. This gain contributed to a broader positive trend in the pharma sector, with the healthcare index trading 0.60% higher. Panacea Biotech and Sudeep Pharma also saw significant increases.